Keywords: پیدا کردن دوز; Dose-finding; Phase 1 designs; Overall success;
مقالات ISI پیدا کردن دوز (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پیدا کردن دوز; Phase I-II; Dose-finding; Multiple populations; Continual reassessment method;
Keywords: پیدا کردن دوز; Stanozolol; Toxicity; Dose-finding; Horse; Osteoarthritis;
Keywords: پیدا کردن دوز; Adaptive design; AZD1386; Data Monitoring Committee; Dose-finding; Interim analysis; Osteoarthritis;
Keywords: پیدا کردن دوز; Bioassay; Dose-finding; Experimental design; Fisher's information; Observed information; Optimal design; Phase I; Response-adaptive design
Keywords: پیدا کردن دوز; Dose-finding; Design; Pharmacokinetics; Paediatrics; Clinical development; Phase I trial;
dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials
Keywords: پیدا کردن دوز; Dose-finding; Maximum tolerated dose; Pharmacokinetics; Phase I clinical trials; R package;
Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study
Keywords: پیدا کردن دوز; In vitro fertilization; gonadotropin-releasing hormone agonist trigger; oocyte donor; dose-finding; triptorelin;
dfcomb: An R-package for phase I/II trials of drug combinations
Keywords: پیدا کردن دوز; Dose-finding; Phase I; Combination; Adaptive design; R package;
Adaptive optimal designs for dose-finding studies based on sigmoid Emax models
Keywords: پیدا کردن دوز; Dose-finding; Adaptive designs; Loewner order; Optimal designs
Research ArticlePhase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
Keywords: پیدا کردن دوز; Dose-finding; Everolimus; Hepatocellular carcinoma; Mammalian target of rapamycin; Sorafenib; HCC; hepatocellular carcinoma; VEGFR; vascular endothelial growth factor receptor; PDGFR; platelet-derived growth factor receptor; SHAR; Sorafenib HCC Assessment
Optimal designs for contingent response models with application to toxicity-efficacy studies
Keywords: پیدا کردن دوز; Dose-finding; Experimental design; Continuation ratio model; Nonlinear response functions; Phase II clinical trials; Bivariate responses;
A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials
Keywords: پیدا کردن دوز; Bayesian; Adaptive design; Dose escalation; Cohort expansion; Dose-finding; Simulation
A dose-finding study of oral misoprostol for labor augmentation
Keywords: پیدا کردن دوز; dose-finding; labor augmentation; oral misoprostol; phase I trial;
Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer: Safety and Efficacy in a Phase 1 Trial
Keywords: پیدا کردن دوز; Pralatrexate; Antifolate; Non-small cell lung cancer; NSCLC; Dose-finding
Penalized optimal designs for dose-finding
Keywords: پیدا کردن دوز; 62K05; 62L05; 62P10; Optimal experimental design; Penalized experimental design; Compound optimal design; Constrained optimal design; Dose-finding; Bivariate binary model;
Some geometric methods for constructing decision criteria based on two-dimensional parameters
Keywords: پیدا کردن دوز; Bayesian statistics; Clinical trials; Dose-finding; Indifference set; Medical decision making; Phase II clinical trial; Trade-offs
Adaptive designs for selecting drug combinations based on efficacy–toxicity response
Keywords: پیدا کردن دوز; Adaptive design; Bivariate probit model; Dose-finding; Dose–response; Drug combination; Early phase clinical trials; Information matrix; Optimal experimental design; Optimal safe dose
Adaptive designs for dose-finding based on efficacy–toxicity response
Keywords: پیدا کردن دوز; Adaptive design; Cox bivariate binary model; Dose-finding; Gumbel logistic regression model; Information matrix; Optimal experimental design; Optimal safe dose; Phase I/II clinical trials